국소 지혈제 시장 규모, 점유율, 동향 분석 보고서 : 종류별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Topical Hemostat Market Size & Trends:

The global topical hemostat market size was valued at USD 5.9 billion in 2024 and is projected to grow at a CAGR of 9.4% from 2025 to 2030. The industry is growing due to rising surgical procedures, increasing trauma cases, and advancements in hemostatic technologies. These products are widely used to control bleeding in surgeries, including cardiovascular, orthopedic, and neurosurgical procedures. The demand is fueled by the need for faster wound healing, reduced surgical complications, and improved patient outcomes. Growing healthcare infrastructure, particularly in emerging markets, and the rise in minimally invasive procedures further drive market growth.

A recent case underscored the limitations of conventional hemostatic materials like gauze, where its unintended presence in a patient post-surgery caused pain, inflammation, and infection. Traditional materials such as gauze and medical bands primarily control surface bleeding but lack adherence to bleeding sites and are prone to contamination. Alternatives like fibrin glue and collagen sponges, though biodegradable, are expensive due to reliance on human or animal-derived proteins.

Researchers have addressed these limitations and developed an innovative bilayer nanofiber membrane hemostat using natural proteins from mussels and silkworm cocoons. This novel hemostat offers strong tissue adhesion, effective bleeding control, and protection against infection. Led by Professor Hyung Joon Cha and a collaborative team from POSTECH, Ewha Womans University, and Seoul St. Mary's Hospital, the research was published in the journal Small in February 2024. The hemostatic agent integrates mussel adhesive proteins, which activate platelets for rapid hemostasis, and silk fibroin from silkworms, modified with methanol vapor to create a hydrophobic nanofiber outer layer. This dual-layer design ensures biocompatibility, biodegradability, and robust infection prevention.

Animal experiments demonstrated the agent's ability to accelerate tissue adhesion and hemostasis in bleeding wounds. Its inner layer enhances adhesion while the outer layer protects against waterborne contaminants and bacteria. These advancements address critical shortcomings in existing hemostatic materials, offering a safer, multifunctional solution for surgical applications. The research team emphasized the agent's potential for real-world surgical settings and its transformative impact on patient care.

The industry benefits from growing awareness of such innovations, as well as funding and research support. This study, supported by Korea's Marine Bio Materials Research Center Program and the National Research Foundation, highlights the importance of government initiatives in driving market growth. As demand for advanced, cost-effective, and biocompatible hemostatic agents rises, the market is poised for substantial expansion, propelled by technological breakthroughs and the continuous pursuit of safer surgical outcomes.

Global Topical Hemostat Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global topical hemostat market report on the basis of type, application, end-use, and region:

• Type Outlook (Revenue, USD Million, 2018 - 2030)
• Fibrin
• Thrombin
• Cellulose
• Collagen
• Gelatin
• Adhesives
• Others
• Application Outlook (Revenue, USD Million, 2018 - 2030)
• General Surgery
• Neurosurgery
• Vascular Surgery
• Cardiovascular Surgery
• Others
• End-use Outlook (Revenue, USD Million, 2018 - 2030)
• Hospitals
• Ambulatory Surgical Centers
• Others
• Region Outlook (Revenue, USD Million, 2018 - 2030)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Application
  • 1.2.3. End-use
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type outlook
  • 2.2.2. Application outlook
  • 2.2.3. End-use outlook
• 2.3. Regional outlook
• 2.4. Competitive Insights

Chapter 3. Topical Hemostat Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Topical Hemostat Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. Topical Hemostat Market: Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Topical Hemostat Market: Type Movement Analysis
• 4.3. Topical Hemostat Market by Type Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 4.5. Fibrin
  • 4.5.1. Fibrin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Thrombin
  • 4.6.1. Thrombin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.7. Cellulose
  • 4.7.1. Cellulose Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.8. Collagen
  • 4.8.1. Collagen Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.9. Gelatin
  • 4.9.1. Gelatin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.10. Adhesives
  • 4.10.1. Adhesives Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.11. Others
  • 4.11.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Topical Hemostat Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Topical Hemostat Market: Application Movement Analysis
• 5.3. Topical Hemostat Market by Application Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 5.5. General Surgery
  • 5.5.1. General Surgery Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Neurosurgery
  • 5.6.1. Neurosurgery Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.7. Vascular Surgery
  • 5.7.1. Vascular Surgery Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.8. Cardiovascular Surgery
  • 5.8.1. Cardiovascular Surgery Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.9. Others
  • 5.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Topical Hemostat Market: End-use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Topical Hemostat Market: End-use Movement Analysis
• 6.3. Topical Hemostat Market by Ens-use Outlook (USD Million)
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 6.5. Hospitals
  • 6.5.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Ambulatory Surgical Centers
  • 6.6.1. Ambulatory Surgical Centers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.7. Others
  • 6.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Topical Hemostat Market: Regional Estimates & Trend Analysis

• 7.1. Regional Dashboard
• 7.2. Regional Topical Hemostat Market movement analysis
• 7.3. Topical Hemostat Market: Regional Estimates & Trend Analysis by Technology & Usability
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 7.5. North America
  • 7.5.1. North America Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.2. U.S.
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Reimbursement scenario
    • 7.5.2.5. U.S. Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. Canada
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Reimbursement scenario
    • 7.5.3.5. Canada Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.4. Mexico
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. Reimbursement scenario
    • 7.5.4.5. Mexico Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Europe
  • 7.6.1. Europe Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.2. UK
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Reimbursement scenario
    • 7.6.2.5. UK Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. Germany
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Reimbursement scenario
    • 7.6.3.5. Germany Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.4. France
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Competitive Scenario
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Reimbursement scenario
    • 7.6.4.5. France Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.5. Italy
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Competitive Scenario
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Reimbursement scenario
    • 7.6.5.5. Italy Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.6. Spain
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Competitive Scenario
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. Reimbursement scenario
    • 7.6.6.5. Spain Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.7. Denmark
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Competitive Scenario
    • 7.6.7.3. Regulatory Framework
    • 7.6.7.4. Reimbursement scenario
    • 7.6.7.5. Denmark Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.8. Sweden
    • 7.6.8.1. Key Country Dynamics
    • 7.6.8.2. Competitive Scenario
    • 7.6.8.3. Regulatory Framework
    • 7.6.8.4. Reimbursement scenario
    • 7.6.8.5. Sweden Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.9. Norway
    • 7.6.9.1. Key Country Dynamics
    • 7.6.9.2. Competitive Scenario
    • 7.6.9.3. Regulatory Framework
    • 7.6.9.4. Reimbursement scenario
    • 7.6.9.5. Norway Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.7. Asia Pacific
  • 7.7.1. Asia Pacific Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.2. Japan
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. Reimbursement scenario
    • 7.7.2.5. Japan Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.3. China
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Reimbursement scenario
    • 7.7.3.5. China Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.4. India
    • 7.7.4.1. Key Country Dynamics
    • 7.7.4.2. Competitive Scenario
    • 7.7.4.3. Regulatory Framework
    • 7.7.4.4. Reimbursement scenario
    • 7.7.4.5. India Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.5. South Korea
    • 7.7.5.1. Key Country Dynamics
    • 7.7.5.2. Competitive Scenario
    • 7.7.5.3. Regulatory Framework
    • 7.7.5.4. Reimbursement scenario
    • 7.7.5.5. South Korea Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.6. Australia
    • 7.7.6.1. Key Country Dynamics
    • 7.7.6.2. Competitive Scenario
    • 7.7.6.3. Regulatory Framework
    • 7.7.6.4. Reimbursement scenario
    • 7.7.6.5. Australia Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.7. Thailand
    • 7.7.7.1. Key Country Dynamics
    • 7.7.7.2. Competitive Scenario
    • 7.7.7.3. Regulatory Framework
    • 7.7.7.4. Reimbursement scenario
    • 7.7.7.5. Thailand Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.8. Latin America
  • 7.8.1. Latin America Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.2. Brazil
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Competitive Scenario
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. Reimbursement scenario
    • 7.8.2.5. Brazil Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.3. Argentina
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Competitive Scenario
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. Reimbursement scenario
    • 7.8.3.5. Argentina Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.9. Middle East & Africa
  • 7.9.1. Middle East & Africa Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.9.2. South Africa
    • 7.9.2.1. Key Country Dynamics
    • 7.9.2.2. Competitive Scenario
    • 7.9.2.3. Regulatory Framework
    • 7.9.2.4. Reimbursement scenario
    • 7.9.2.5. South Africa Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.9.3. Saudi Arabia
    • 7.9.3.1. Key Country Dynamics
    • 7.9.3.2. Competitive Scenario
    • 7.9.3.3. Regulatory Framework
    • 7.9.3.4. Reimbursement scenario
    • 7.9.3.5. Saudi Arabia Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.9.4. UAE
    • 7.9.4.1. Key Country Dynamics
    • 7.9.4.2. Competitive Scenario
    • 7.9.4.3. Regulatory Framework
    • 7.9.4.4. Reimbursement scenario
    • 7.9.4.5. UAE Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.9.5. Kuwait
    • 7.9.5.1. Key Country Dynamics
    • 7.9.5.2. Competitive Scenario
    • 7.9.5.3. Regulatory Framework
    • 7.9.5.4. Reimbursement scenario
    • 7.9.5.5. Kuwait Topical Hemostat Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Market Participant Categorization
• 8.2. Key Company Profiles
  • 8.2.1. BD
    • 8.2.1.1. Company overview
    • 8.2.1.2. Financial performance
    • 8.2.1.3. Type benchmarking
    • 8.2.1.4. Strategic initiatives
  • 8.2.2. Medicom
    • 8.2.2.1. Company overview
    • 8.2.2.2. Financial performance
    • 8.2.2.3. Type benchmarking
    • 8.2.2.4. Strategic initiatives
  • 8.2.3. Baxter
    • 8.2.3.1. Company overview
    • 8.2.3.2. Financial performance
    • 8.2.3.3. Type benchmarking
    • 8.2.3.4. Strategic initiatives
  • 8.2.4. HemoSonics
    • 8.2.4.1. Company overview
    • 8.2.4.2. Financial performance
    • 8.2.4.3. Type benchmarking
    • 8.2.4.4. Strategic initiatives
  • 8.2.5. Hemostasis, LLC
    • 8.2.5.1. Company overview
    • 8.2.5.2. Financial performance
    • 8.2.5.3. Type benchmarking
    • 8.2.5.4. Strategic initiatives
  • 8.2.6. Medline Industries
    • 8.2.6.1. Company overview
    • 8.2.6.2. Financial performance
    • 8.2.6.3. Type benchmarking
    • 8.2.6.4. Strategic initiatives
  • 8.2.7. Pfizer Inc.
    • 8.2.7.1. Company overview
    • 8.2.7.2. Financial performance
    • 8.2.7.3. Type benchmarking
    • 8.2.7.4. Strategic initiatives
  • 8.2.8. Johnson & Johnson
    • 8.2.8.1. Company overview
    • 8.2.8.2. Financial performance
    • 8.2.8.3. Type benchmarking
    • 8.2.8.4. Strategic initiatives
  • 8.2.9. HemCon Medical Technologies Inc.
    • 8.2.9.1. Company overview
    • 8.2.9.2. Financial performance
    • 8.2.9.3. Type benchmarking
    • 8.2.9.4. Strategic initiatives
  • 8.2.10. Integra LifeSciences
    • 8.2.10.1. Company overview
    • 8.2.10.2. Financial performance
    • 8.2.10.3. Type benchmarking
    • 8.2.10.4. Strategic initiatives
  • 8.2.11. Teleflex Incorporated
    • 8.2.11.1. Company overview
    • 8.2.11.2. Financial performance
    • 8.2.11.3. Type benchmarking
    • 8.2.11.4. Strategic initiatives